Cargando…

A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine

OBJECTIVE: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada. METHODS: We developed an epidemiologic model to evaluate allocation strategies defined by age and ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirwin, Erin, Rafferty, Ellen, Harback, Kate, Round, Jeff, McCabe, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209775/
https://www.ncbi.nlm.nih.gov/pubmed/34138458
http://dx.doi.org/10.1007/s40273-021-01037-2
_version_ 1783709196703760384
author Kirwin, Erin
Rafferty, Ellen
Harback, Kate
Round, Jeff
McCabe, Christopher
author_facet Kirwin, Erin
Rafferty, Ellen
Harback, Kate
Round, Jeff
McCabe, Christopher
author_sort Kirwin, Erin
collection PubMed
description OBJECTIVE: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada. METHODS: We developed an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness and cost of vaccine. The model simulated hypothetical immunisation scenarios within a dynamic context, capturing concurrent public health strategies and population behavioural changes. RESULTS: In a scenario with 80% vaccine effectiveness, 40% population coverage and prioritisation of those over the age of 60 years at high risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs $292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs $118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies. CONCLUSIONS: Our results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01037-2.
format Online
Article
Text
id pubmed-8209775
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-82097752021-06-17 A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine Kirwin, Erin Rafferty, Ellen Harback, Kate Round, Jeff McCabe, Christopher Pharmacoeconomics Original Research Article OBJECTIVE: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada. METHODS: We developed an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness and cost of vaccine. The model simulated hypothetical immunisation scenarios within a dynamic context, capturing concurrent public health strategies and population behavioural changes. RESULTS: In a scenario with 80% vaccine effectiveness, 40% population coverage and prioritisation of those over the age of 60 years at high risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs $292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs $118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies. CONCLUSIONS: Our results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01037-2. Springer International Publishing 2021-06-17 2021 /pmc/articles/PMC8209775/ /pubmed/34138458 http://dx.doi.org/10.1007/s40273-021-01037-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Kirwin, Erin
Rafferty, Ellen
Harback, Kate
Round, Jeff
McCabe, Christopher
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
title A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
title_full A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
title_fullStr A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
title_full_unstemmed A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
title_short A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
title_sort net benefit approach for the optimal allocation of a covid-19 vaccine
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209775/
https://www.ncbi.nlm.nih.gov/pubmed/34138458
http://dx.doi.org/10.1007/s40273-021-01037-2
work_keys_str_mv AT kirwinerin anetbenefitapproachfortheoptimalallocationofacovid19vaccine
AT raffertyellen anetbenefitapproachfortheoptimalallocationofacovid19vaccine
AT harbackkate anetbenefitapproachfortheoptimalallocationofacovid19vaccine
AT roundjeff anetbenefitapproachfortheoptimalallocationofacovid19vaccine
AT mccabechristopher anetbenefitapproachfortheoptimalallocationofacovid19vaccine
AT kirwinerin netbenefitapproachfortheoptimalallocationofacovid19vaccine
AT raffertyellen netbenefitapproachfortheoptimalallocationofacovid19vaccine
AT harbackkate netbenefitapproachfortheoptimalallocationofacovid19vaccine
AT roundjeff netbenefitapproachfortheoptimalallocationofacovid19vaccine
AT mccabechristopher netbenefitapproachfortheoptimalallocationofacovid19vaccine